Significant Revenue Growth
BrainsWay reported a 26% year-over-year increase in revenue for Q3 2024, reaching $10.5 million. Full-year 2024 revenue guidance was increased to $40-41 million, representing 26% to 29% growth over 2023.
Positive Financial Performance
BrainsWay achieved positive quarterly net income for the fourth consecutive quarter and positive adjusted EBITDA and cash flow from operations for the fifth consecutive quarter. Q3 2024 net income was approximately $650,000, compared to a net loss of $230,000 in Q3 2023.
Strategic Investment and Strong Cash Position
BrainsWay completed a strategic private investment equity financing with Valor Equity Partners for approximately $20 million, bringing the pro forma cash position to $68.4 million.
Expansion in International Markets
BrainsWay placed 15 new Deep TMS systems in Taiwan and South Korea, indicating continued commercial success in the East Asian market.
Regulatory and Reimbursement Achievements
Approval for the reimbursement of Deep TMS therapy for PTSD patients by the Israeli Ministry of Defense Rehabilitation Department was granted.
Clinical and R&D Progress
BrainsWay's multicenter clinical trial for an accelerated treatment protocol is fully underway, with potential FDA approval in 2025.